Skip to main content
SpringerLink
Log in

Management of patients with advanced epithelial ovarian cancer: a European survey

  • Gynecologic Oncology
  • Published:
Archives of Gynecology and Obstetrics Aims and scope Submit manuscript

Abstract

Background

The aim of this study was to assess current European practices in the management of patients with advanced epithelial ovarian cancer in 2021.

Methods

A 58-question electronic survey was distributed anonymously to the members of six European learned societies. Initial diagnostic workup and staging, pathological data, surgical data, treatments and follow-up strategies were assessed.

Results

A total of 171 participants from 17 European countries responded to emailed surveys. Most participants were experienced practitioners (superior than 15 years of experience) specializing in gynecology-obstetrics (29.8%), surgical oncology (25.1%), and oncogynecology (21.6%). According to most (64.8%) participants, less than 50% of patients were eligible for primary debulking surgery. Variations in the rate of primary debulking surgery depending on the country of origin of the practitioners were observed in this study. The LION study criteria were applied in 70.4% of cases during PDS and 27.1% after chemotherapy. In cases of BRCA1-2 mutations, olaparib was given by 75.0–84.8% of respondents, whereas niraparib was given in cases of BRCA wild-type diseases.

Conclusions

This study sheds light on current practices and attitudes regarding the management of patients with advanced epithelial ovarian cancer in Europe in 2021.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Data availability

The data presented in this study are available on request from the corresponding author.

References

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424. https://doi.org/10.3322/caac.21492

    Article  PubMed  Google Scholar 

  2. Pavlidis N, Rassy E, Vermorken JB, Assi T, Kattan J, Boussios S, Smith-Gagen J (2021) The outcome of patients with serous papillary peritoneal cancer, fallopian tube cancer, and epithelial ovarian cancer by treatment Eras: 27 years data from the SEER registry. Cancer Epidemiol 75:102045

    Article  PubMed  Google Scholar 

  3. Colombo N, Sessa C, du Bois A, Ledermann J, McCluggage WG, McNeish I, Morice P, Pignata S, Ray-Coquard I, Vergote I et al (2019) ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†. Ann Oncol 30:672–705. https://doi.org/10.1093/annonc/mdz062

    Article  CAS  PubMed  Google Scholar 

  4. Chi DS, Eisenhauer EL, Zivanovic O, Sonoda Y, Abu-Rustum NR, Levine DA, Guile MW, Bristow RE, Aghajanian C, Barakat RR (2009) Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol 114:26–31. https://doi.org/10.1016/j.ygyno.2009.03.018

    Article  PubMed  Google Scholar 

  5. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20:1248–1259. https://doi.org/10.1200/JCO.2002.20.5.1248

    Article  PubMed  Google Scholar 

  6. Moschetta M, Boussios S, Rassy E, Samartzis EP, Funingana G, Uccello M (2020) Neoadjuvant treatment for newly diagnosed advanced ovarian cancer: where do we stand and where are we going? Ann Transl Med 8:1710

    Article  PubMed  PubMed Central  Google Scholar 

  7. van Driel WJ, Koole SN, Sikorska K, Schagen van Leeuwen JH, Schreuder HWR, Hermans RHM, de Hingh IHJT, van der Velden J, Arts HJ, Massuger LFAG et al (2018) Hyperthermic intraperitoneal chemotherapy in ovarian cancer. New England J Med 378:230–240. https://doi.org/10.1056/NEJMoa1708618

    Article  Google Scholar 

  8. Fagotti A, Ferrandina MG, Vizzielli G, Pasciuto T, Fanfani F, Gallotta V, Margariti PA, Chiantera V, Costantini B, Alletti SG et al (2020) Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850). Int J Gynecol Cancer. https://doi.org/10.1136/ijgc-2020-001640

  9. Colombo N, Ledermann JA, ESMO Guidelines Committee (2021) Electronic address: clinicalguidelines@esmo.org updated treatment recommendations for newly diagnosed epithelial ovarian carcinoma from the ESMO clinical practice guidelines. Ann Oncol 32:1300–1303. https://doi.org/10.1016/j.annonc.2021.07.004

    Article  CAS  PubMed  Google Scholar 

  10. Norell CH, Butler J, Farrell R, Altman A, Bentley J, Cabasag CJ, Cohen PA, Fegan S, Fung-Kee-Fung M, Gourley C et al (2020) Exploring international differences in ovarian cancer treatment: a comparison of clinical practice guidelines and patterns of care. Int J Gynecol Cancer 30:1748–1756. https://doi.org/10.1136/ijgc-2020-001403

    Article  PubMed  PubMed Central  Google Scholar 

  11. Drouin L, Guani B, Balaya V, Azaïs H, Betrian S, Bolze P-A, Dabi Y, Kerbage Y, Sanson C, Zaccarini F et al (2021) Results of a 2021 french national survey on management of patients with advanced stage epithelial ovarian cancer. J Clin Med 10:4829. https://doi.org/10.3390/jcm10214829

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Lavoue V, Huchon C, Akladios C, Alfonsi P, Bakrin N, Ballester M, Bendifallah S, Bolze P-A, Bonnet F, Bourgin C et al (2019) Management of epithelial ovarian cancer. Short text drafted from the French joint recommendations of FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY and endorsed by INCa. Bull Cancer 106:354–370. https://doi.org/10.1016/j.bulcan.2019.01.014

    Article  PubMed  Google Scholar 

  13. Fotopoulou C, Hall M, Cruickshank D, Gabra H, Ganesan R, Hughes C, Kehoe S, Ledermann J, Morrison J, Naik R et al (2017) British Gynaecological cancer society (BGCS) epithelial ovarian/fallopian tube/primary peritoneal cancer guidelines: recommendations for practice. Eur J Obstet Gynecol Reprod Biol 213:123–139. https://doi.org/10.1016/j.ejogrb.2017.04.016

    Article  PubMed  Google Scholar 

  14. Hall JP, Chang J, Moon R, Higson O, Byrne K, Doherty JP, Cappelleri JC (2020) Real-world treatment patterns in patients with advanced (Stage III–IV) ovarian cancer in the USA and Europe. Future Oncol. https://doi.org/10.2217/fon-2020-0083

    Article  PubMed  Google Scholar 

  15. Audibert C, Perlaky A, Stuntz M, Glass D (2017) Variability in the therapeutic management of advanced ovarian cancer patients: a five-country survey of oncologists. Drug Des Devel Ther 11:3471–3479. https://doi.org/10.2147/DDDT.S151420

    Article  PubMed  PubMed Central  Google Scholar 

  16. Fagotti A, Ferrandina MG, Vizzielli G, Pasciuto T, Fanfani F, Gallotta V, Margariti PA, Chiantera V, Costantini B, Gueli Alletti S et al (2020) Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850). Int J Gynecol Cancer 30:1657–1664. https://doi.org/10.1136/ijgc-2020-001640

    Article  PubMed  Google Scholar 

  17. Vergote I, Amant F, Ehlen T (2010) Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. The New Engl J Med. https://doi.org/10.1056/NEJMoa0908806

    Article  PubMed  Google Scholar 

  18. Kehoe S, Hook J, Nankivell M, Jayson GC, Kitchener H, Lopes T, Luesley D, Perren T, Bannoo S, Mascarenhas M et al (2015) Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled. Non-Inferiority Trial Lancet 386:249–257. https://doi.org/10.1016/S0140-6736(14)62223-6

    Article  PubMed  Google Scholar 

  19. Coleridge SL, Bryant A, Lyons TJ, Goodall RJ, Kehoe S, Morrison J (2019) Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD005343.pub4

    Article  PubMed  PubMed Central  Google Scholar 

  20. Vergote I, Coens C, Nankivell M, Kristensen GB, Parmar MKB, Ehlen T, Jayson GC, Johnson N, Swart AM, Verheijen R et al (2018) Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials. Lancet Oncol 19:1680–1687. https://doi.org/10.1016/S1470-2045(18)30566-7

    Article  PubMed  Google Scholar 

  21. Chéreau E, Ballester M, Selle F, Cortez A, Daraï E, Rouzier R (2010) Comparison of peritoneal carcinomatosis scoring methods in predicting resectability and prognosis in advanced ovarian cancer. Am J Obstet Gynecol 202(178):e1-178.e10. https://doi.org/10.1016/j.ajog.2009.10.856

    Article  Google Scholar 

  22. Chi DS, Eisenhauer EL, Lang J, Huh J, Haddad L, Abu-Rustum NR, Sonoda Y, Levine DA, Hensley M, Barakat RR (2006) What is the optimal goal of primary cytoreductive surgery for bulky stage iiic epithelial ovarian carcinoma (EOC)? Gynecol Oncol 103:559–564. https://doi.org/10.1016/j.ygyno.2006.03.051

    Article  CAS  PubMed  Google Scholar 

  23. Lyons YA, Reyes HD, McDonald ME, Newtson A, Devor E, Bender DP, Goodheart MJ, Gonzalez Bosquet J (2020) Interval debulking surgery is not worth the wait: a national cancer database study comparing primary cytoreductive surgery versus neoadjuvant chemotherapy. Int J Gynecol Cancer 30:845–852. https://doi.org/10.1136/ijgc-2019-001124

    Article  PubMed  PubMed Central  Google Scholar 

  24. Moore K, Colombo N, Scambia G, Kim B-G, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS et al (2018) Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 379:2495–2505. https://doi.org/10.1056/NEJMoa1810858

    Article  CAS  PubMed  Google Scholar 

  25. Delga B, Classe J-M, Houvenaeghel G, Blache G, Sabiani L, El Hajj H, Andrieux N, Lambaudie E (2020) 30 years of experience in the management of stage iii and iv epithelial ovarian cancer: impact of surgical strategies on survival. Cancers (Basel) 12:768. https://doi.org/10.3390/cancers12030768

    Article  CAS  PubMed  Google Scholar 

  26. González-Martín A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, McCormick C, Lorusso D, Hoskins P, Freyer G et al (2019) Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 381:2391–2402. https://doi.org/10.1056/NEJMoa1910962

    Article  PubMed  Google Scholar 

  27. Ray-Coquard I, Pautier P, Pignata S, Pérol D, González-Martín A, Berger R, Fujiwara K, Vergote I, Colombo N, Mäenpää J et al (2019) Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med 381:2416–2428. https://doi.org/10.1056/NEJMoa1911361

    Article  CAS  PubMed  Google Scholar 

  28. Alejandra M, Gertych W, Pomel C, Ferron G, Lusque A, Angeles MA, Lambaudie E, Rouzier R, Bakrin N, Golfier F et al (2021) Adherence to French and ESGO quality indicators in ovarian cancer surgery: an ad-hoc analysis from the prospective multicentric CURSOC study. Cancers (Basel) 13:1593. https://doi.org/10.3390/cancers13071593

    Article  PubMed  Google Scholar 

  29. Akladios C, Daraï É, Golfier F, Lecuru F, Collinet P, Uzan C, Lavoué V, Guyon F, Ferron G, Querleu D (2021) Certification nationale pour la chirurgie des cancers gynécologiques. Bull Cancer 108:806–812. https://doi.org/10.1016/j.bulcan.2021.03.019

    Article  PubMed  Google Scholar 

  30. Querleu D, Planchamp F, Chiva L, Fotopoulou C, Barton D, Cibula D, Aletti G, Carinelli S, Creutzberg C, Davidson B et al (2016) European society of gynaecologic oncology quality indicators for advanced ovarian cancer surgery. Int J Gynecol Cancer 26:1354–1363. https://doi.org/10.1097/IGC.0000000000000767

    Article  PubMed  Google Scholar 

  31. Ferrero A, Ditto A, Giorda G, Gadducci A, Greggi S, Daniele A, Fuso L, Panuccio E, Scaffa C, Raspagliesi F et al (2014) Secondary cytoreductive surgery for isolated lymph node recurrence of epithelial ovarian cancer: a multicenter study. Eur J Surg Oncol 40:891–898. https://doi.org/10.1016/j.ejso.2013.11.026

    Article  CAS  PubMed  Google Scholar 

  32. du Bois A, Reuss A, Harter P, Pujade-Lauraine E, Ray-Coquard I, Pfisterer J (2010) Arbeitsgemeinschaft gynaekologische onkologie studiengruppe ovarialkarzinom; groupe d’investigateurs nationaux pour l’etude des cancers ovariens potential role of lymphadenectomy in advanced ovarian cancer: a combined exploratory analysis of three prospectively randomized phase III multicenter trials. J Clin Oncol 28:1733–1739. https://doi.org/10.1200/JCO.2009.25.3617

    Article  PubMed  Google Scholar 

  33. Zhou J, Shan G, Chen Y (2016) The effect of lymphadenectomy on survival and recurrence in patients with ovarian cancer: a systematic review and meta-analysis. Jpn J Clin Oncol 46:718–726. https://doi.org/10.1093/jjco/hyw068

    Article  PubMed  Google Scholar 

  34. Panici PB, Maggioni A, Hacker N, Landoni F, Ackermann S, Campagnutta E, Tamussino K, Winter R, Pellegrino A, Greggi S et al (2005) Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. J Natl Cancer Inst 97:560–566. https://doi.org/10.1093/jnci/dji102

    Article  PubMed  Google Scholar 

  35. Harter P, Sehouli J, Lorusso D, Reuss A, Vergote I, Marth C, Kim J-W, Raspagliesi F, Lampe B, Aletti G et al (2019) A randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms. N Engl J Med 380:822–832. https://doi.org/10.1056/NEJMoa1808424

    Article  PubMed  Google Scholar 

  36. Morgan RJ, Alvarez RD, Armstrong DK, Burger RA, Chen LM, Copeland L;, et al (2013) NCCN clinical practice guidelines in oncology (NCCN Guidelines). Ovarian Cancer Incl Fallopian Tube Cancer Prim Peritoneal Cancer. 11:1199–1209

    CAS  Google Scholar 

  37. Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C et al (2011) A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 365:2484–2496. https://doi.org/10.1056/NEJMoa1103799

    Article  CAS  PubMed  Google Scholar 

  38. Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, Mannel RS, Homesley HD, Fowler J, Greer BE et al (2011) Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365:2473–2483. https://doi.org/10.1056/NEJMoa1104390

    Article  CAS  PubMed  Google Scholar 

  39. Ghose A, Gullapalli SVN, Chohan N, Bolina A, Moschetta M, Rassy E, Boussios S (2022) Applications of proteomics in ovarian cancer: dawn of a new era. Proteomes 10:16

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Hardesty MM, Krivak T, Wright GS, Hamilton E, Fleming EL, Gupta D, Keeton E, Chen J, Clements A, Gray HJ et al (2020) Phase II OVARIO study of niraparib + bevacizumab therapy in advanced ovarian cancer following front-line platinum-based chemotherapy with bevacizumab. Gynecol Oncol 159:3–4. https://doi.org/10.1016/j.ygyno.2020.06.006

    Article  Google Scholar 

  41. Shah S, Cheung A, Kutka M, Sheriff M, Boussios S (2022) Epithelial ovarian cancer: providing evidence of predisposition genes. Int J Environ Res Public Health 19:8113

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Pujol P, Barberis M, Beer P, Friedman E, Piulats JM, Capoluongo ED, Garcia Foncillas J, Ray-Coquard I, Penault-Llorca F, Foulkes WD et al (2021) Clinical practice guidelines for BRCA1 and BRCA2 genetic testing. Eur J Cancer 146:30–47. https://doi.org/10.1016/j.ejca.2020.12.023

    Article  CAS  PubMed  Google Scholar 

  43. Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, Gelber RD, de Azambuja E, Fielding A, Balmaña J et al (2021) Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med 384:2394–2405. https://doi.org/10.1056/NEJMoa2105215

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Boussios S, Rassy E, Shah S, Ioannidou E, Sheriff M, Pavlidis N (2021) Aberrations of DNA repair pathways in prostate cancer: a cornerstone of precision oncology. Expert Opin Ther Targets 25:329–333

    Article  PubMed  Google Scholar 

Download references

Funding

This research received no external funding.

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, University Hospital, Strasbourg, France

    Floriane Jochum & Cherif Akladios

  2. Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, Paris, France

    Floriane Jochum

  3. Department of Surgical Oncology, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse (IUCT), Oncopole, Toulouse, France

    Martina Aida Angeles

  4. Department of Obstetrics and Gynecology, Foch Hospital, Suresnes, France

    Vincent Balaya

  5. Department of Gynecology, CHU de Limoges, Limoges, France

    Leonor Drouin

  6. Academic Teaching Hospital of Heidelberg University, Baden-Baden, Germany

    Tanja Nikolova

  7. Women-Mother-Child Department, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

    Patrice Mathevet

  8. Breast, Gynecology and Reconstructive Surgery Unit, Curie Institute, Paris, France

    Fabrice Lécuru

  9. Gynecologic and Breast Oncologic Surgery Department, Georges Pompidou European Hospital, Paris, France

    Henri Azais

  10. Department of Medical Oncology, IUCT Oncopole, Toulouse, France

    Sarah Betrian

  11. Department of Gynecology, CHU Lyon Sud, Pierre-Bénite, France

    Pierre-Adrien Bolze

  12. Department of Gynecology, Tenon Hospital, AP-HP, Paris, France

    Yohann Dabi & Sofiane Bendifallah

  13. Department of Gynecology, Jeanne de Flandre Hospital, Lille, France

    Yohan Kerbage

  14. Surgical Oncology Department, Gustave Roussy Institute, Villejuif, France

    Claire Sanson & François Zaccarini

  15. Surgical Oncology Department, Bergonié Institute, Bordeaux, France

    Fréderic Guyon

  16. Department of Obstetrics and Gynecology, National Taiwan University Hospital Hsin-Chu Branch, Hsinchu, Taiwan

    Arthur Hsu

  17. Oncology Department, University Hospital, Limoges, France

    Elise Deluche

  18. Department of Obstetrics and Gynecology, Fribourg Hospital, Fribourg, Switzerland

    Benedetta Guani

Authors
  1. Floriane Jochum
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Martina Aida Angeles
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Vincent Balaya
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Leonor Drouin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tanja Nikolova
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Patrice Mathevet
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Fabrice Lécuru
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Henri Azais
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Sarah Betrian
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Pierre-Adrien Bolze
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Yohann Dabi
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Yohan Kerbage
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Claire Sanson
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. François Zaccarini
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Fréderic Guyon
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Cherif Akladios
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Arthur Hsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Sofiane Bendifallah
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Elise Deluche
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. Benedetta Guani
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Conceptualization, FJ, MAA, VB, LD, TN, PM, HA, SB, P-AB, YD, YK, CS, FZ, H-CH, SB, ED and BG; Data curation, FJ and VB; Formal analysis, FJ and VB; Investigation, FJ and VB; Methodology, FJ; Supervision, VB, FL, FG, CA, ED and BG; Validation, FJ, FL, YK, FG and CA; Visualization, FJ; Writing—original draft, FJ; Writing—review & editing, FJ, MAA, VB, LD, TN, PM, FL, HA, SB, P-AB, YD, CS, FZ, FG, CA, H-CH, SB, ED and BG.

Corresponding author

Correspondence to Floriane Jochum.

Ethics declarations

Conflicts of interest

The authors declare no conflict of interest.

Informed consent

Not applicable.

Institutional review board statement

Not applicable.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 15 KB)

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jochum, F., Angeles, M.A., Balaya, V. et al. Management of patients with advanced epithelial ovarian cancer: a European survey. Arch Gynecol Obstet 308, 535–549 (2023). https://doi.org/10.1007/s00404-023-06948-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00404-023-06948-3

Keywords

Search

Navigation